Free shipping on all orders over $ 500

Human PD-L1 inhibitor V

Cat. No. M21327

All AbMole products are for research use only, cannot be used for human consumption.

Human PD-L1 inhibitor V  Structure
Size Price Availability Quantity
10mg USD 280  USD280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd value of 3.32 μM that inhibits the binding of human PD-1/PD-L1.Sequence:Leu-Asp-Tyr-Val-Asn-Arg-Arg-Lys-Met-Tyr-Gln.

Chemical Information
Molecular Weight 1485.71
Formula C65H104N20O18S
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Javier Cortes, et al. N Engl J Med. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

[2] Kohei Shitara, et al. Nature. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

[3] Christine N Spencer, et al. Science. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

[4] Aditya Bardia, et al. N Engl J Med. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

[5] Thomas Powles, et al. N Engl J Med. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Related PD-1/PD-L1 Products
PD-1/PD-L1-IN-9

PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model.

NSC622608 

NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM.

PD-L1-IN-1 

PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM.

SL-279252

SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours.

Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

  Catalog
Abmole Inhibitor Catalog




Keywords: Human PD-L1 inhibitor V supplier, PD-1/PD-L1, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.